Clinical trials: Rifampin
Tuberculosis, Pulmonary
A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB
To assess outcome of treatment and safety among patients with rifampicin-resistant isoniazid-susceptible pulmonary tuberculosis treated with a novel regimen consisting of isoniazid, bedaquiline, and moxifloxacin throughout for 6…
- Trial name
- NCT06526039
- Testing
- a novel short regimen
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Tuberculosis, Pulmonary
Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB
The development of efficacious, safe, and shorter treatment regimens could significantly improve TB management and treatment success rates.
- Trial name
- ESCAPE-TB (NCT04856644)
- Testing
- 4-month rifapentine-based regimen
- Where
- 4 sites in Taiwan
- Volunteers
- 333 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Type 2 Diabetes Mellitus
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
The purpose of this study is to examine the drug-drug interaction when given the study drug, bexagliflozin, with three commonly prescribed medications, probenecid, verapamil or rifampin.
- Trial name
- NCT03296800
- Testing
- Bexagliflozin, Probenecid, Rifampin
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Theracos
Pulmonary Tuberculosis
Using Biomarkers to Predict TB Treatment Duration
Background: Tuberculosis (TB) is a bacterial lung infection. Typical treatment using anti-TB drugs lasts about 6 months. Some people with less severe TB might not need to take the drugs that long.
- Trial name
- NCT02821832
- Testing
- Saliva collection, Urine collection, Sputum collection
- Where
- South Africa
- Volunteers
- 946 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Brucellosis
Fluoroquinolone-Doxycycline Oral Treatments for Adults With Uncomplicated Brucellosis
Brucellosis is a common zoonotic infectious disease. The standard dual regimen of doxycycline combined with rifampicin is widely used for uncomplicated brucellosis.
- Trial name
- BRUCE-U (NCT07887126)
- Testing
- Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Shihezi University
RSV Infection
Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects
A Non-Randomized, Open-Label, Three-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Rifampin, and Quinidine on the Pharmacokinetics and Safety of EDP-938 in Healthy Subjects
- Trial name
- NCT03755778
- Testing
- EDP-938, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Leprosy
Uniform Multidrug Therapy Regimen for Leprosy Patients
The purpose of this randomized trial is to verify if leprosy patients, despite of their classification, can be treated with the same regimen without compromising patient cure and acceptability of the treatment.
- Trial name
- U-MDT (NCT00669643)
- Testing
- PB 6 doses - Rifampicin and Dapsone, PB 6 doses - Rifampicin, Clofazimine and Dapsone, MB 12 doses - Rifampicin, Clofazimine and Dapsone
- Where
- 2 sites in Brazil
- Volunteers
- 859 people
- Sponsor
- University of Brasilia
Male, Healthy Normal Subjects
Rifampin Drug-Drug Interaction Study With Lurasidone HCl
The effect of rifampin on the pharmacokinetics of lurasidone
- Trial name
- NCT01082276
- Testing
- Lurasidone HCl
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sumitomo Pharma America, Inc.
Tuberculosis, Multidrug Resistant Tuberculosis
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
The objective of this work is to measure the early bactericidal activity of tedizolid, to compare it with the bactericidal activity of linezolid (reference molecule for the treatment of multidrug-resistant tuberculosis) and with…
- Trial name
- TEDITUB (NCT05534750)
- Testing
- Tedizolid arm (SIVEXTRO®), Linezolid arm (ZYVOXID®), Standard quadruple therapy arm
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumors, Lymphoma
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.
- Trial name
- NCT01844583
- Testing
- Alisertib, Esomeprazole, Rifampin
- Where
- 7 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Nocturia
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
The purpose of this study is to investigate the potential for co-administration of strong inhibitors or inducers of CYP3A4 to alter the pharmacokinetics of fedovapagon.
- Trial name
- NCT02440841
- Testing
- fedovapagon, Itraconazole, rifampicin
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Pulmonary Tuberculosis TB in Sputum: (+) Microscopy
Pilot Clinical Trial of PRS TB Regimen I - Phase II
Tuberculosis is the current leading cause of death due to an identifiable infectious agent worldwide. The current standard regimen for tuberculosis requires a patient to take drug combination (isoniazid, rifampicin, ethambutol…
- Trial name
- NCT03561753
- Testing
- Group A (the standard 2HRZE/4HR regimen）, Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)
- Where
- 4 sites in China
- Volunteers
- 97 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Granulomatous Mastitis
Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis
Granulomatous lobular mastitis (GLM) is a rare benign breast disease that is difficult to distinguish from breast cancer based on clinical and imaging findings, and there is currently no standard treatment.
- Trial name
- NCT06565845
- Testing
- Surgery, triple anti-tuberculosis drug
- Where
- China
- Volunteers
- 350 people
- Sponsor
- First Affiliated Hospital of Harbin Medical University
Hidradenitis Suppurativa
Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients
The study evaluates the efficacy of an adapted antibiotherapy in Hurley stage 2 active Hidradenitis Suppurativa patients versus tetracycline derivative
- Trial name
- ABCESS2 (NCT05821478)
- Where
- 4 sites in France
- Volunteers
- 92 people
- Sponsor
- Institut Pasteur
Adult Solid Neoplasm
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
This randomized phase I trial studies the side effects and best dose of RO4929097 in treating patients with advanced solid tumors.
- Trial name
- NCT01218620
- Testing
- Gamma-Secretase Inhibitor RO4929097, Ketoconazole, Rifampin
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Healthy
Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.
This is a Phase 1 open label, 2 period, single fixed sequence study designed to evaluate the effect of repeat dose oral rifampin on single dose PF 04965842 PK after a single 200 mg oral dose in healthy subjects.
- Trial name
- NCT03637790
- Testing
- PF-04965842, rifampin
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine
This study is aimed to examine the possible interactions of sublingual and intravenous buprenorphine with rifampicin.
- Trial name
- NCT01854489
- Testing
- Rifampicin, Buprenorphine
- Where
- Finland
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Healthy, Drug Drug Interaction
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
Open-label, parallel, 2-arm, fixed-sequence study to investigate the effect of coadministration of a CYP3A4 inhibitor (Cohort 1, itraconazole multiple dose) and CYP3A4 inducer (Cohort 2, rifampin multiple dose) on the plasma PK…
- Trial name
- NCT04606537
- Testing
- Itraconazole, Rifampin, KBP-5074
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- KBP Biosciences
Healthy Subjects
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects
This study is a single-center, open-lable and fixed sequence test conducted in healthy subjects to evaluate the pharmacokinetic effects of Itraconazole and Rifampicin on a single dose of SY-5007 Oral administration.
- Trial name
- NCT06332053
- Testing
- SY-5007, Itraconazole, Rifampin
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shouyao Holdings (Beijing) Co. LTD
Healthy
Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers
The study will consist of two open-label periods, a Treatment Period I (deferasirox) and a Treatment Period II (rifampicin+deferasirox). At least 18 subjects are expected to complete both treatment periods as per protocol.
- Trial name
- NCT00419172
- Testing
- Deferasirox, Rifampicin
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Novartis